;PMID: 9224809
;source_file_1873.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:41..186] = [t:41..186]
;2)section:[e:190..233] = [t:190..233]
;3)section:[e:237..331] = [t:237..331]
;4)sentence:[e:335..505] = [t:335..505]
;5)sentence:[e:506..589] = [t:506..589]
;6)sentence:[e:590..896] = [t:590..896]
;7)sentence:[e:897..1153] = [t:897..1153]
;8)sentence:[e:1154..1320] = [t:1154..1320]
;9)sentence:[e:1321..1639] = [t:1321..1639]
;10)sentence:[e:1641..1792] = [t:1641..1792]
;11)sentence:[e:1793..2229] = [t:1793..2229]
;12)section:[e:2233..2277] = [t:2233..2277]

;section 0 Span:0..35
;Mol Pharmacol. 1997 Jul;52(1):30-7.
(SEC
  (FRAG (NNP:[0..3] Mol) (NNP:[4..13] Pharmacol) (.:[13..14] .)
        (CD:[15..19] 1997) (NNP:[20..23] Jul) (::[23..24] ;) (CD:[24..26] 52)
        (-LRB-:[26..27] -LRB-) (CD:[27..28] 1) (-RRB-:[28..29] -RRB-)
        (::[29..30] :) (CD:[30..32] 30) (::[32..33] -) (CD:[33..34] 7)
        (.:[34..35] .)))

;sentence 1 Span:41..186
;Cytokine gene expression during ontogeny in murine thymus on activation of
;the  aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
;[121..146]:substance:"aryl hydrocarbon receptor"
;[150..185]:substance:"2,3,7,8-tetrachlorodibenzo-p-dioxin"
(SENT
  (NP-HLN
    (NP (NN:[41..49] Cytokine) (NN:[50..54] gene) (NN:[55..65] expression))
    (PP-TMP (IN:[66..72] during)
      (NP
        (NP (NN:[73..81] ontogeny))
        (PP (IN:[82..84] in)
          (NP (JJ:[85..91] murine) (NN:[92..98] thymus)))
        (PP (IN:[99..101] on)
          (NP
            (NP (NN:[102..112] activation))
            (PP (IN:[113..115] of)
              (NP (DT:[116..119] the)
                
                (NML (NN:[121..125] aryl) (NN:[126..137] hydrocarbon))
                (NN:[138..146] receptor)))
            (PP (IN:[147..149] by)
              (NP (NN:[150..185] 2,3,7,8-tetrachlorodibenzo-p-dioxin)))))))
    (.:[185..186] .)))

;section 2 Span:190..233
;Lai ZW, Hundeiker C, Gleichmann E, Esser C.
(SEC
  (FRAG (NNP:[190..193] Lai) (NNP:[194..196] ZW) (,:[196..197] ,)
        (NNP:[198..207] Hundeiker) (NNP:[208..209] C) (,:[209..210] ,)
        (NNP:[211..221] Gleichmann) (NNP:[222..223] E) (,:[223..224] ,)
        (NNP:[225..230] Esser) (NNP:[231..232] C) (.:[232..233] .)))

;section 3 Span:237..331
;Medical Institute of Environmental Hygiene, Heinrich-Heine-University of 
;Dusseldorf, Germany.
(SEC
  (FRAG (NNP:[237..244] Medical) (NNP:[245..254] Institute) (IN:[255..257] of)
        (NNP:[258..271] Environmental) (NNP:[272..279] Hygiene) (,:[279..280] ,)
        (NNP:[281..289] Heinrich) (HYPH:[289..290] -) (NNP:[290..295] Heine)
        (HYPH:[295..296] -) (NNP:[296..306] University) (IN:[307..309] of)
        (NNP:[311..321] Dusseldorf) (,:[321..322] ,) (NNP:[323..330] Germany)
        (.:[330..331] .)))

;sentence 4 Span:335..505
;2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) binds and activates the aryl 
;hydrocarbon receptor (Ah-R), an endogenous transcription factor that is 
;expressed in the thymus.
;[335..370]:substance:"2,3,7,8-Tetrachlorodibenzo-p-dioxin"
;[372..376]:substance:"TCDD"
;[402..428]:substance:"aryl  hydrocarbon receptor"
;[430..434]:substance:"Ah-R"
;[451..471]:substance:"transcription factor"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[335..370] 2,3,7,8-Tetrachlorodibenzo-p-dioxin))
      (NP (-LRB-:[371..372] -LRB-) (NN:[372..376] TCDD) (-RRB-:[376..377] -RRB-)))
    (VP (VBZ:[378..383] binds) (CC:[384..387] and) (VBZ:[388..397] activates)
      (NP
        (NP
          (NP (DT:[398..401] the)
            
            (NML (NN:[402..406] aryl) (NN:[408..419] hydrocarbon))
            (NN:[420..428] receptor))
          (NP (-LRB-:[429..430] -LRB-) (NN:[430..434] Ah-R)
              (-RRB-:[434..435] -RRB-)))
        (,:[435..436] ,)
        (NP
          (NP (DT:[437..439] an) (JJ:[440..450] endogenous)
             (NN:[451..464] transcription) (NN:[465..471] factor))
          (SBAR
            (WHNP-1 (WDT:[472..476] that))
            (S
              (NP-SBJ-1 (-NONE-:[476..476] *T*))
              (VP (VBZ:[477..479] is)
                (VP (VBN:[481..490] expressed)
                  (NP-1 (-NONE-:[490..490] *))
                  (PP-LOC (IN:[491..493] in)
                    (NP (DT:[494..497] the) (NN:[498..504] thymus))))))))))
    (.:[504..505] .)))

;sentence 5 Span:506..589
;TCDD exposure leads, among other effects, to thymus  atrophy and
;immunosuppression.
;[506..510]:substance:"TCDD"
(SENT
  (S
    (NP-SBJ (NN:[506..510] TCDD) (NN:[511..519] exposure))
    (VP (VBZ:[520..525] leads) (,:[525..526] ,)
      (PP (IN:[527..532] among)
        (NP (JJ:[533..538] other) (NNS:[539..546] effects)))
      (,:[546..547] ,)
      (PP-CLR (TO:[548..550] to)
        (NP
          (NP (NN:[551..557] thymus) (NN:[559..566] atrophy))
          (CC:[567..570] and)
          (NP (NN:[571..588] immunosuppression)))))
    (.:[588..589] .)))

;sentence 6 Span:590..896
;We previously analyzed the interference of TCDD  with differentiation
;processes in fetal thymus organ cultures and found that in  the presence of
;TCDD, the proliferation rate of immature (CD4- CD8- and CD4-  CD8+ HSA+)
;thymocytes is inhibited, whereas the maturation along the CD4/CD8  path is
;accelerated.
;[633..637]:substance:"TCDD"
;[736..740]:substance:"TCDD"
(SENT
  (S
    (NP-SBJ (PRP:[590..592] We))
    (ADVP-TMP (RB:[593..603] previously))
    (VP
      (VP (VBD:[604..612] analyzed)
        (NP
          (NP (DT:[613..616] the) (NN:[617..629] interference))
          (PP (IN:[630..632] of)
            (NP (NN:[633..637] TCDD))))
        (PP (IN:[639..643] with)
          (NP (NN:[644..659] differentiation) (NNS:[660..669] processes)))
        (PP-LOC (IN:[670..672] in)
          (NP (JJ:[673..678] fetal) (NN:[679..685] thymus) (NN:[686..691] organ)
              (NNS:[692..700] cultures))))
      (CC:[701..704] and)
      (VP (VBD:[705..710] found)
        (SBAR (IN:[711..715] that)
          (S
            (PP (IN:[716..718] in)
              (NP
                (NP (DT:[720..723] the) (NN:[724..732] presence))
                (PP (IN:[733..735] of)
                  (NP (NN:[736..740] TCDD)))))
            (,:[740..741] ,)
            (NP-SBJ-2
              (NP (DT:[742..745] the) (NN:[746..759] proliferation)
                  (NN:[760..764] rate))
              (PP (IN:[765..767] of)
                (NP
                  (ADJP (JJ:[768..776] immature)
                    (PP (-LRB-:[777..778] -LRB-)
                      (NP
                        (NP (NN:[778..781] CD4) (SYM:[781..782] -))
                        (NP (NN:[783..786] CD8) (SYM:[786..787] -))
                        (CC:[788..791] and)
                        (NP (NN:[792..795] CD4) (SYM:[795..796] -))
                        (NP (NN:[798..801] CD8) (SYM:[801..802] +))
                        (NP (NN:[803..806] HSA) (SYM:[806..807] +)))
                      (-RRB-:[807..808] -RRB-)))
                  (NNS:[809..819] thymocytes))))
            (VP (VBZ:[820..822] is)
              (VP (VBN:[823..832] inhibited)
                (NP-2 (-NONE-:[832..832] *))
                (,:[832..833] ,)
                (SBAR-ADV (IN:[834..841] whereas)
                  (S
                    (NP-SBJ-1
                      (NP (DT:[842..845] the) (NN:[846..856] maturation))
                      (PP (IN:[857..862] along)
                        (NP (DT:[863..866] the)
                          (NML (NN:[867..870] CD4) (SYM:[870..871] /)
                               (NN:[871..874] CD8))
                          (NN:[876..880] path))))
                    (VP (VBZ:[881..883] is)
                      (VP (VBN:[884..895] accelerated)
                        (NP-1 (-NONE-:[895..895] *))))))))))))
    (.:[895..896] .)))

;sentence 7 Span:897..1153
;Moreover, the differentiation of thymocytes is skewed by  TCDD at < or = 40%
;(compared with approximately 15% without TCDD) of the CD8  single-positive
;subset of future cytotoxic T cells, and apparently more cells  audition for
;and pass positive selection.
;[955..959]:substance:"TCDD"
;[963..973]:quantitative-value:"< or = 40%"
;[989..1006]:quantitative-value:"approximately 15%"
;[1015..1019]:substance:"TCDD"
(SENT
  (S
    (S
      (ADVP (RB:[897..905] Moreover))
      (,:[905..906] ,)
      (NP-SBJ-4
        (NP (DT:[907..910] the) (NN:[911..926] differentiation))
        (PP (IN:[927..929] of)
          (NP (NNS:[930..940] thymocytes))))
      (VP (VBZ:[941..943] is)
        (VP (VBN:[944..950] skewed)
          (NP-4 (-NONE-:[950..950] *))
          (PP (IN:[951..953] by)
            (NP-LGS (NN:[955..959] TCDD)))
          (PP (IN:[960..962] at)
            (NP
              (NP
                
                (QP (SYM:[963..964] <) (CC:[965..967] or) (SYM:[968..969] =)
                    (CD:[970..972] 40))
                (NN:[972..973] %)
                (PRN (-LRB-:[974..975] -LRB-)
                  (VP (VBN:[975..983] compared)
                    (NP (-NONE-:[983..983] *))
                    (PP-CLR (IN:[984..988] with)
                      (NP
                        (NP
                          (QP (RB:[989..1002] approximately)
                              (CD:[1003..1005] 15))
                          (NN:[1005..1006] %))
                        (PP (IN:[1007..1014] without)
                          (NP (NN:[1015..1019] TCDD))))))
                  (-RRB-:[1019..1020] -RRB-)))
              (PP (IN:[1021..1023] of)
                (NP
                  (NP (DT:[1024..1027] the) (NN:[1028..1031] CD8)
                    (ADJP (JJ:[1033..1039] single) (HYPH:[1039..1040] -)
                          (JJ:[1040..1048] positive))
                    (NN:[1049..1055] subset))
                  (PP (IN:[1056..1058] of)
                    (NP (JJ:[1059..1065] future) (JJ:[1066..1075] cytotoxic)
                        (NN:[1076..1077] T) (NNS:[1078..1083] cells))))))))))
    (,:[1083..1084] ,) (CC:[1085..1088] and)
    (S
      (ADVP (RB:[1089..1099] apparently))
      (NP-SBJ (JJR:[1100..1104] more) (NNS:[1105..1110] cells))
      (VP
        (VP (VBP:[1112..1120] audition)
          (PP-CLR (IN:[1121..1124] for)
            (NP-1 (-NONE-:[1124..1124] *RNR*))))
        (CC:[1125..1128] and)
        (VP (VBP:[1129..1133] pass)
          (NP-1 (-NONE-:[1133..1133] *RNR*)))
        (NP-1 (JJ:[1134..1142] positive) (NN:[1143..1152] selection))))
    (.:[1152..1153] .)))

;sentence 8 Span:1154..1320
;The fetal murine thymus expresses  functional Ah-R mRNA, as shown by reverse
;transcription-polymerase chain  reaction and TCDD-inducible CYP1A1 and CYP1B1
;expression.
;[1200..1209]:substance:"Ah-R mRNA"
;[1245..1255]:substance:"polymerase"
;[1276..1280]:substance:"TCDD"
;[1291..1297]:cyp450:"CYP1A1"
;[1302..1308]:cyp450:"CYP1B1"
(SENT
  (S
    (NP-SBJ (DT:[1154..1157] The) (JJ:[1158..1163] fetal)
            (JJ:[1164..1170] murine) (NN:[1171..1177] thymus))
    (VP (VBZ:[1178..1187] expresses)
      (NP (JJ:[1189..1199] functional)
         (NN:[1200..1204] Ah-R) (NN:[1205..1209] mRNA))
      (,:[1209..1210] ,)
      (PP-MNR (IN:[1211..1213] as)
        (S-NOM
          (NP-SBJ-3 (-NONE-:[1213..1213] *))
          (VP (VBN:[1214..1219] shown)
            (NP-3 (-NONE-:[1219..1219] *))
            (PP (IN:[1220..1222] by)
              (NP-LGS
                (NP
                  (NML (JJ:[1223..1230] reverse) (NN:[1231..1244] transcription))
                  (HYPH:[1244..1245] -) (NN:[1245..1255] polymerase)
                   (NN:[1256..1261] chain) (NN:[1263..1271] reaction))
                (CC:[1272..1275] and)
                (NP
                  (NP
                    (ADJP-1 (NN:[1276..1280] TCDD) (HYPH:[1280..1281] -)
                            (JJ:[1281..1290] inducible))
                    (NN:[1291..1297] CYP1A1)
                    (NML-2 (-NONE-:[1297..1297] *P*)))
                  (CC:[1298..1301] and)
                  (NP
                    (ADJP-1 (-NONE-:[1301..1301] *P*))
                    (NN:[1302..1308] CYP1B1)
                    (NML-2 (NN:[1309..1319] expression))))))))))
    (.:[1319..1320] .)))

;sentence 9 Span:1321..1639
;Because the  differentiation of thymocytes is to a considerable extent
;controlled by  cytokines and many cytokine genes are potential targets of the
;Ah-R due to  Ah-R-binding elements (xenobiotic response elements) in their
;promoters, we  analyzed the cytokine expression in fetal thymus organ culture
;exposed to TCDD.
;[1470..1474]:substance:"Ah-R"
;[1483..1487]:substance:"Ah-R"
;[1506..1516]:substance:"xenobiotic"
;[1545..1554]:substance:"promoters"
;[1634..1638]:substance:"TCDD"
(SENT
  (S
    (SBAR-PRP (IN:[1321..1328] Because)
      (S
        (S
          (NP-SBJ-2
            (NP (DT:[1329..1332] the) (NN:[1334..1349] differentiation))
            (PP (IN:[1350..1352] of)
              (NP (NNS:[1353..1363] thymocytes))))
          (VP (VBZ:[1364..1366] is)
            (VP
              (PP-EXT (TO:[1367..1369] to)
                (NP (DT:[1370..1371] a) (JJ:[1372..1384] considerable)
                    (NN:[1385..1391] extent)))
              (VBN:[1392..1402] controlled)
              (NP-2 (-NONE-:[1402..1402] *))
              (PP (IN:[1403..1405] by)
                (NP-LGS (NNS:[1407..1416] cytokines))))))
        (CC:[1417..1420] and)
        (S
          (NP-SBJ (JJ:[1421..1425] many) (NN:[1426..1434] cytokine)
                  (NNS:[1435..1440] genes))
          (VP (VBP:[1441..1444] are)
            (NP-PRD
              (NP (JJ:[1445..1454] potential) (NNS:[1455..1462] targets))
              (PP (IN:[1463..1465] of)
                (NP (DT:[1466..1469] the) (NN:[1470..1474] Ah-R)))
              (ADJP (IN:[1475..1478] due)
                (PP (TO:[1479..1481] to)
                  (NP
                    (NP
                      (NP
                        (ADJP (NN:[1483..1487] Ah-R) (HYPH:[1487..1488] -)
                              (VBG:[1488..1495] binding))
                        (NNS:[1496..1504] elements))
                      (NP (-LRB-:[1505..1506] -LRB-)
                          (JJ:[1506..1516] xenobiotic)
                          (NN:[1517..1525] response) (NNS:[1526..1534] elements)
                          (-RRB-:[1534..1535] -RRB-)))
                    (PP-LOC (IN:[1536..1538] in)
                      (NP (PRP$:[1539..1544] their) (NNS:[1545..1554] promoters)))))))))))
    (,:[1554..1555] ,)
    (NP-SBJ (PRP:[1556..1558] we))
    (VP (VBD:[1560..1568] analyzed)
      (NP (DT:[1569..1572] the) (NN:[1573..1581] cytokine)
          (NN:[1582..1592] expression))
      (PP-LOC (IN:[1593..1595] in)
        (NP
          (NP-1 (JJ:[1596..1601] fetal) (NN:[1602..1608] thymus)
                (NN:[1609..1614] organ) (NN:[1615..1622] culture))
          (VP (VBN:[1623..1630] exposed)
            (NP-1 (-NONE-:[1630..1630] *))
            (PP-CLR (TO:[1631..1633] to)
              (NP (NN:[1634..1638] TCDD)))))))
    (.:[1638..1639] .)))

;sentence 10 Span:1641..1792
;Fetal thymi were cultured from gestation day 15 for < or = 8 days, thus
;covering  ex vivo the period after population of the thymus anlage until
;birth.
;[1682..1685]:quantitative-units:"day"
;[1686..1688]:quantitative-value:"15"
;[1693..1701]:quantitative-value:"< or = 8"
;[1702..1706]:quantitative-units:"days"
(SENT
  (S
    (NP-SBJ-2 (JJ:[1641..1646] Fetal) (NNS:[1647..1652] thymi))
    (VP (VBD:[1653..1657] were)
      (VP (VBN:[1658..1666] cultured)
        (NP-2 (-NONE-:[1666..1666] *))
        (PP-TMP (IN:[1667..1671] from)
          (NP (NN:[1672..1681] gestation) (NN:[1682..1685] day)
              (CD:[1686..1688] 15)))
        (PP-TMP (IN:[1689..1692] for)
          (NP
            (QP (SYM:[1693..1694] <) (CC:[1695..1697] or) (SYM:[1698..1699] =)
                (CD:[1700..1701] 8))
            (NNS:[1702..1706] days)))
        (,:[1706..1707] ,)
        (S-MNR
          (NP-SBJ (-NONE-:[1707..1707] *))
          (ADVP (RB:[1708..1712] thus))
          (VP (VBG:[1713..1721] covering)
            (ADVP (FW:[1723..1725] ex) (FW:[1726..1730] vivo))
            (NP-TMP
              (NP (DT:[1731..1734] the) (NN:[1735..1741] period))
              (PP (IN:[1742..1747] after)
                (NP
                  (NP (NN:[1748..1758] population))
                  (PP (IN:[1759..1761] of)
                    (NP (DT:[1762..1765] the) (NN:[1766..1772] thymus)
                        (NN:[1773..1779] anlage)))))
              (PP (IN:[1780..1785] until)
                (NP (NN:[1786..1791] birth))))))))
    (.:[1791..1792] .)))

;sentence 11 Span:1793..2229
;We show  with semiquantitative reverse transcription-polymerase chain
;reaction that more  interleukin (IL)-1beta, IL-2, IL-6, tumor growth factor
;(TGF)-beta3, and tumor  necrosis factor-alpha are produced in TCDD-exposed
;thymi, whereas other  cytokines (e.g., TGF-beta1, PAI-2, or IL-4) are only
;slightly up- and  down-modulated during the culture period or not modulated
;at all (e.g.,  IL-1beta, IL-7, interferon-gamma, and TGF-beta2).
;[1846..1856]:substance:"polymerase"
;[1883..1905]:substance:"interleukin (IL)-1beta"
;[1907..1911]:substance:"IL-2"
;[1913..1917]:substance:"IL-6"
;[1919..1950]:substance:"tumor growth factor (TGF)-beta3"
;[1956..1984]:substance:"tumor  necrosis factor-alpha"
;[2001..2005]:substance:"TCDD"
;[2036..2045]:substance:"cytokines"
;[2053..2062]:substance:"TGF-beta1"
;[2064..2069]:substance:"PAI-2"
;[2074..2078]:substance:"IL-4"
;[2180..2188]:substance:"IL-1beta"
;[2190..2194]:substance:"IL-7"
;[2196..2212]:substance:"interferon-gamma"
;[2218..2227]:substance:"TGF-beta2"
(SENT
  (S
    (NP-SBJ (PRP:[1793..1795] We))
    (VP (VBP:[1796..1800] show)
      (PP-MNR (IN:[1802..1806] with)
        (NP (JJ:[1807..1823] semiquantitative)
          (NML (JJ:[1824..1831] reverse) (NN:[1832..1845] transcription))
          (HYPH:[1845..1846] -) (NN:[1846..1856] polymerase)
           (NN:[1857..1862] chain) (NN:[1863..1871] reaction)))
      (SBAR (IN:[1872..1876] that)
        (S
          (NP-SBJ-5
            (NP
              (ADJP-4 (JJR:[1877..1881] more))
              
              (NML
                (NML (NN:[1883..1894] interleukin))
                (NML (-LRB-:[1895..1896] -LRB-) (NN:[1896..1898] IL)
                     (-RRB-:[1898..1899] -RRB-)))
              (HYPH:[1899..1900] -) (NN:[1900..1905] 1beta))
            (,:[1905..1906] ,)
            (NP
              (ADJP-4 (-NONE-:[1906..1906] *P*))
              (NN:[1907..1911] IL-2))
            (,:[1911..1912] ,)
            (NP
              (ADJP-4 (-NONE-:[1912..1912] *P*))
              (NN:[1913..1917] IL-6))
            (,:[1917..1918] ,)
            (NP
              (ADJP-4 (-NONE-:[1918..1918] *P*))
              
              (NML
                (NML (NN:[1919..1924] tumor) (NN:[1925..1931] growth)
                     (NN:[1932..1938] factor))
                (NML (-LRB-:[1939..1940] -LRB-) (NN:[1940..1943] TGF)
                     (-RRB-:[1943..1944] -RRB-)))
              (HYPH:[1944..1945] -) (NN:[1945..1950] beta3))
            (,:[1950..1951] ,) (CC:[1952..1955] and)
            (NP
              (ADJP-4 (-NONE-:[1955..1955] *P*))
              
              (NML (NN:[1956..1961] tumor) (NN:[1963..1971] necrosis))
              (NN:[1972..1984] factor-alpha)))
          (VP (VBP:[1985..1988] are)
            (VP (VBN:[1989..1997] produced)
              (NP-5 (-NONE-:[1997..1997] *))
              (PP-LOC (IN:[1998..2000] in)
                (NP
                  (ADJP (NN:[2001..2005] TCDD) (HYPH:[2005..2006] -)
                        (VBN:[2006..2013] exposed))
                  (NNS:[2014..2019] thymi))))
            (,:[2019..2020] ,)
            (SBAR-ADV (IN:[2021..2028] whereas)
              (S
                (NP-SBJ-2 (JJ:[2029..2034] other) (NNS:[2036..2045] cytokines)
                  (PRN (-LRB-:[2046..2047] -LRB-)
                    (NP
                      (ADVP (FW:[2047..2051] e.g.))
                      (,:[2051..2052] ,) (NN:[2053..2062] TGF-beta1)
                       (,:[2062..2063] ,) (NN:[2064..2069] PAI-2)
                       (,:[2069..2070] ,) (CC:[2071..2073] or)
                       (NN:[2074..2078] IL-4))
                    (-RRB-:[2078..2079] -RRB-)))
                (VP (VBP:[2080..2083] are)
                  (VP
                    (VP
                      (VP
                        (ADVP (RB:[2084..2088] only) (RB:[2089..2097] slightly))
                        (VP (RB:[2098..2100] up) (HYPH:[2100..2101] -)
                          (VP-1 (-NONE-:[2101..2101] *P*)))
                        (CC:[2102..2105] and)
                        (VP (RB:[2107..2111] down) (HYPH:[2111..2112] -)
                          (VP-1 (VBN:[2112..2121] modulated))))
                      (PP-TMP (IN:[2122..2128] during)
                        (NP (DT:[2129..2132] the) (NN:[2133..2140] culture)
                            (NN:[2141..2147] period))))
                    (CC:[2148..2150] or)
                    (VP (RB:[2151..2154] not)
                      (VP (VBN:[2155..2164] modulated)
                        (NP-2 (-NONE-:[2164..2164] *))
                        (PP (IN:[2165..2167] at)
                          (NP (DT:[2168..2171] all)))))
                    (PRN (-LRB-:[2172..2173] -LRB-)
                      (NP
                        (ADVP (FW:[2173..2177] e.g.))
                        (,:[2177..2178] ,) (NN:[2180..2188] IL-1beta)
                         (,:[2188..2189] ,) (NN:[2190..2194] IL-7)
                         (,:[2194..2195] ,) (NN:[2196..2212] interferon-gamma)
                         (,:[2212..2213] ,) (CC:[2214..2217] and)
                         (NN:[2218..2227] TGF-beta2))
                      (-RRB-:[2227..2228] -RRB-))))))))))
    (.:[2228..2229] .)))

;section 12 Span:2233..2277
;PMID: 9224809 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2233..2237] PMID) (::[2237..2238] :) (CD:[2239..2246] 9224809)
        (NN:[2247..2248] -LSB-) (NNP:[2248..2254] PubMed) (::[2255..2256] -)
        (NN:[2257..2264] indexed) (IN:[2265..2268] for)
        (NNP:[2269..2276] MEDLINE) (-RRB-:[2276..2277] -RSB-)))
